Skip to content

Here’s Why NeuroSense Therapeutics (NRSN) Stock Soared 288% Today

Ollie Martin - AskTraders News writer
Ollie Martin trader
Updated 21 Mar 2022

Trade NRSN Stock Your Capital Is At Risk

Key points:

  • NeuroSense recieves FDA approval for a pharmacokinetic study of PrimeC
  • The treatment is geared towards inhibiting the progression of ALS, a largely incurable disease
  • The company is also working on promising Alzheimers and Parkinsons treatments

Shares in NeuroSense Therapeutics (NASDAQ: NRSN) soared nearly 300% today. The company, which specializes in developing treatments for severe neurodegenerative diseases, announced some promising news today. The company announced that it has received full clearing from the FDA to start a pharmacokinetic study of PrimeC – a potential treatment that might inhibit the progression of ALS, an incurable neurodegenerative disease. 

PrimeC is a new combination of two existing FDA-approved drugs; ciprofloxacin and celecoxib. The unique combination works by targeting various mechanisms of ALS that contribute to motor neuron degeneration. The treatment was granted Orphan Drug Designation by the FDA and the European Medicines Agency. A Phase IIa clinical trial has already been underway with PrimeC meeting its safety and efficacy endpoints including reducing respiratory deterioration. A Phase IIb trial is set to follow suit in Q2 2022. 

Read Also: Best Healthcare Stocks To Buy Right Now

NeuroSense CEO Alon Ben-Noon stated:

“Data from our Phase IIa clinical study confirmed that PrimeC is a novel therapy with the potential to help people with ALS and address a $3 billion market in need of a more effective treatment” 

This isn’t the only alluring story to come out of NeuroSense lately. The company is also working on ground-breaking Alzheimers and Parkinsons' treatments, with preclinical data expected in the second half of 2022. For investors, there is a lot of future potential in NeuroSense. Albeit, inventors should be wary about short-term volatility and will want to wait for a more optimum entry point after today’s rally starts to fade.

Ollie Martin - AskTraders News writer
Oliver is a financial writer and analyst specialising in the US stock market, with years of personal experience in understanding micro/macroeconomic structures, market trends and fundamental analysis.